New Reporting Requirements and Compliance Strategies

In this episode of the Healthcare & Life Sciences Podcast, hosts Adam Hunter, Assurance Services Partner, and Carolyn Smith Driscoll, Tax Credits & Incentives Advisory, continue the conversation around R&D tax credits, focusing on the evolving reporting and documentation requirements. Together, they discuss the IRS's revised Form 6765 and the shift toward project-level reporting.

Tune in to learn more about:

• Key changes to Form 6765 and how they are reshaping R&D tax credit reporting requirements.
• The new business component reporting requirements and why project-level tracking is becoming increasingly important.
• What effective documentation looks like and how companies can support their claims with audit-ready records.
• The practical impact of enhanced IRS reporting expectations on life sciences organizations.
• Steps companies can take today to prepare for future compliance requirements and strengthen their R&D credit processes.

Join the conversation for insights on what life sciences companies need to do now to strengthen documentation, improve compliance, and prepare for increased scrutiny of R&D credit claims.

Questions? Contact Us: https://www.cbh.com/contact/connect-me-with-a-professional/

Life Sciences R&D Tax Credits: Common Pitfalls and Recent Tax Change

Continuing the R&D tax credit series, this episode of the Healthcare & Life Sciences Podcast covers the complexity around qualifying opportunities in digital health and AI-enabled medical technologies. Hosts Adam Hunter, Assurance Services Partner, and Carolyn Smith Driscoll, Tax Credits & Incentives Advisory, discuss common mistakes that can reduce or jeopardize credits, key documentation and audit readiness considerations.

Key Topics

• How software as a medical device (SaMD), AI, and digital health innovations can create significant R&D tax credit opportunities.
• Common pitfalls that lead companies to underclaim credits or create audit challenges, including insufficient documentation and funded research issues.
• Which costs may qualify for the credit, including employee wages, supplies, and certain contract research expenses.
• The importance of building audit-ready documentation and tracking activities at the business component level.
• Recent legislative changes and planning opportunities that could improve cash flow and enhance the value of R&D investments.

Join the conversation for these insights and to learn more about the impact of recent legislative changes on R&D tax treatment and cash flow planning.

In the first episode of the Healthcare & Life Sciences Podcast, hosts Adam Hunter, Assurance[HR1.1] Services Partner, and Carolyn Smith Driscoll, Tax Credits & Incentives Advisory, will explore the many ways R&D tax credits impact the life sciences.

In this first episode, Adam and Carolyn discuss what qualifies as R&D, where organizations commonly miss opportunities, and how proper documentation can help maximize credits while reducing audit risk.

Tune in to learn more about:

• Understanding the fundamentals of R&D tax credits for life sciences companies.
• Identifying qualifying activities across pharmaceuticals, biotech, medical devices, and diagnostics.
• Navigating clinical trial and research-related credit opportunities.
• Recognizing often-overlooked opportunities in process development and manufacturing scale-up.
• Strengthening documentation to support claims and prepare for potential audits.

Questions? Contact Us: https://www.cbh.com/contact/connect-me-with-a-professional/

Learn more about Cherry Bekaert's Life Sciences Industry Services - https://www.cbh.com/industries/healthcare-life-sciences/life-sciences/